Table 3.
Changes in the plasma and hepatic lipids, atherogenic index (AI), and coronary artery index (CRI) in HFD-fed rats receiving 8-week treatment with myricetin or fenofibrate.
| Variable (s) | RCD-fed | HFD-fed | ||||
|---|---|---|---|---|---|---|
| vehicle | Vehicle | Myricetin (mg kg−1 per day) | Fenofibrate | |||
| 75 | 150 | 300 | (100 mg kg−1 per day) | |||
| Plasma TC (mg dL−1) | 71.4 ± 6.7d | 143.2 ± 11.9b | 128.4 ± 9.5b | 109.6 ± 7.7a, c | 98.3 ± 7.3a, c | 84.2 ± 8.0d |
| Plasma TG (mg dL−1) | 55.7 ± 5.9d | 134.5 ± 5.7b | 116.4 ± 6.1b | 99.8 ± 4.7b, c | 84.3 ± 4.3b, c | 65.6 ± 4.7d |
| Plasma LDL-C (mg dL−1) | 31.2 ± 3.3d | 103.2 ± 3.9b | 84.9 ± 5.3b,c | 66.2 ± 4.7b,c | 49.5 ± 4.1a, d | 40.4 ± 4.3d |
| Plasma HDL-C (mg dL−1) | 45.6 ± 3.1d | 26.4 ± 3.2b | 30.5 ± 3.5b | 37.1 ± 2.9a, c | 41.7 ± 3.1d | 43.6 ± 4.4d |
| Plasma FFAs (mg dL−1) | 27.6 ± 2.7d | 63.8 ± 4.1b | 56.9 ± 4.3b | 48.5 ± 3.8b, c | 38.7 ± 3.2a, d | 34.2 ± 3.5d |
| Hepatic TC (mg g−1) | 2.6 ± 0.8d | 5.2 ± 0.7b | 4.6 ± 0.5b | 4.3 ± 0.4a | 3.4 ± 0.3c | 3.1 ± 0.5c |
| Hepatic TG (mg g−1) | 9.0 ± 1.1d | 19.0 ± 1.2b | 17.8 ± 1.4b | 17.2 ± 1.1a | 12.5 ± 1.2c | 11.1 ± 0.8c |
| AI | 0.7 ± 0.2d | 3.9 ± 0.2b | 2.8 ± 0.1b | 1.8 ± 0.3a, c | 1.2 ± 0.2a, d | 0.9 ± 0.3d |
| CRI | 1.6 ± 0.2d | 5.5 ± 0.6b | 4.2 ± 0.5b | 2.9 ± 0.4a, c | 2.2 ± 0.3d | 1.9 ± 0.4d |
Myricetin or fenofibrate was dissolved in distilled water for oral administration at the desired doses in a volume of 2 mL kg−1 once a day into HFD-fed rats. The vehicle (distilled water) used to dissolve the tested medications was given at the same volume. All data represented as the mean ± SEM. a P < .05 and b P < .01 compared to the values of vehicle-treated RCD-fed rats in each group, respectively. c P < .05 and d P < .01 compared to the values of vehicle-treated HFD-fed rats in each group, respectively.